Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000153 | 0.80 | CA1 (0.47) | CA1CA2KMT2AMIFSMN1; SMN2 | |
| SCHEMBL20704282 | 0.78 | CA2 (0.67) | CA1CA2KMT2AMIFSMN1; SMN2 | |
| SCHEMBL14209244 | 0.78 | CA1 (0.55) | CA1CA2KMT2ASMN1; SMN2ZDHHC7 | |
| SCHEMBL5701456 | 0.77 | CA1 (0.44) | CA1CA2KMT2AMIFSMN1; SMN2 | |
| SCHEMBL16863501 | 0.75 | CA1 (0.42) | CA1CA2KMT2AMIFSMN1; SMN2 | |
| SCHEMBL6363454 | 0.75 | CA1 (0.42) | CA1CA2KMT2AMIFSMN1; SMN2 | |
| SCHEMBL960501 | 0.75 | CA1 (0.42) | CA1CA2KMT2AMIFSMN1; SMN2 | |
| SCHEMBL16863503 | 0.75 | CA1 (0.42) | CA1CA2KMT2AMIFSMN1; SMN2 | |
| SCHEMBL14619500 | 0.75 | CA1 (0.38) | CA1CA2KMT2ASMN1; SMN2MME | |
| SCHEMBL11323003 | 0.72 | CA1 (0.40) | CA1CA2KMT2AMIFSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023015223-A9 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023015223-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |